EGFR and esophageal cancer: Our study demonstrated that DTLL was superior to free LDM alone in pancreatic cancer in both in vivo and in vitro, similar to observations from previous reports in the treatments of ovarian carcinoma9 and esophageal cancer.10 In the present study, we selected the PDX model (PA1338) with a higher level of EGFR expression in pancreatic tumor to confirm that DTLL had potent antineoplastic efficacy (Figure 6E), further indicating that its highly potent antitumor activity was predominately attributed to its specifically targeting EGFR.